Get the Stockscreener App
89.15
0.88%
-0.79
After Hours:
89.15
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $89.15, with a volume of 1.48M.
It is down -0.88% in the last 24 hours and down -0.73% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$89.94
Open:
$89.51
24h Volume:
1.48M
Relative Volume:
1.20
Market Cap:
$44.10B
Revenue:
$9.91B
Net Income/Loss:
$1.02B
P/E Ratio:
43.49
EPS:
2.05
Net Cash Flow:
$665.00M
1W Performance:
-3.72%
1M Performance:
-0.73%
6M Performance:
-9.23%
1Y Performance:
+1.13%
1-Day Range:
$88.06
$89.64
1-Week Range:
$88.06
$94.81
52-Week Range:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
89.15 | 44.10B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
493.72 | 176.09B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
224.92 | 64.58B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
225.79 | 33.17B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
35.85 | 18.30B | 17.28B | 108.00M | 391.00M | 0.20 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Contact Lenses Market Forecast Report and Company Analysis - GlobeNewswire
Dry Eye Disease Market Projected To Witness Substantial Growth, 2025-2032: Novartis AG, Alcon Inc., Cipla - EIN News
Alcon, Lens.com Settle 7-Year Trademark Fight In NY - Law360
Deutsche Bank lifts Alcon stock price target to CHF92 from CHF82 - Investing.com Australia
Deutsche Bank lifts Alcon stock price target to CHF92 from CHF82 By Investing.com - Investing.com South Africa
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles - MSN
Alcon projects $10.2B-$10.4B revenue in 2025 with strong product launches - MSN
Alcon Inc. Just Recorded A 7.8% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Alcon Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
Alcon’s Earnings Call: Record Sales & Strategic Growth - TipRanks
Alcon class action alleges eye drops contaminated with fungus - Top Class Actions
Mizuho raises Alcon stock price target to $115, maintains Outperform By Investing.com - Investing.com Canada
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters - sharewise
Alcon Canada Strengthens its Commitment to Astigmatic Patients w - GuruFocus.com
Alcon Inc. (NYSE:ALC) Q4 2024 Earnings Call Transcript - Insider Monkey
Mizuho raises Alcon stock price target to $115, maintains Outperform - Investing.com
Alcon Inc (ALC) Full Year 2024 Earnings Call Highlights: Strong Financial Performance and ... - Yahoo Finance
Alcon Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Alcon Reports Sales Increase in Fourth Quarter and Full-Year 2024, Contact Lens Sales Hit Double-Digit Growth - Vision Monday
Alcon Reports Strong Financial Performance and Growth - TipRanks
Alcon’s Strong Q4 Performance and Strategic Growth Initiatives Earn Buy Rating from Analyst - TipRanks
Alcon Earnings: Ends the Year With Solid Results and Prepares for Innovation-Filled 2025 - Morningstar
Alcon's 2025 Looks Fruitful as New Innovation and Solid Execution Spark Market Penetration - Morningstar
Alcon forecasts revenue growth in 2025, ready to cope with tariffs - TradingView
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours - Yahoo Finance
Alcon’s Mixed Q4 FY24 Results Lead to Hold Rating Amid Promising Pipeline and Strategic Growth Focus - TipRanks
RBC Flags Potential 'Small' Downgrade to Alcon Consensus After FY25 Guidance -February 26, 2025 at 06:37 am EST - Marketscreener.com
Alcon’s Strong Q4 Performance and Growth Prospects Justify Buy Rating - TipRanks
Alcon beats Q4 sales, shares jump despite FX headwinds in 2025 - Investing.com Canada
Alcon: stock market hails reassuring outlook -February 26, 2025 at 05:48 am EST - Marketscreener.com
Alcon Growth Projections In Line With Market Expectations - Finimize
Alcon eyes revenue growth in 2025 after in-line results -February 26, 2025 at 02:03 am EST - Marketscreener.com
Alcon eyes revenue growth in 2025 after in-line results - TradingView
Alcon Inc. announces an Equity Buyback for $750 million worth of its shares. -February 25, 2025 at 04:31 pm EST - Marketscreener.com
Alcon Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Alcon’s Strong Q4 Performance and Market Share Gains Reinforce Buy Rating Despite Lower 2025 Guidance - TipRanks
Alcon Inc. Reports Strong 2024 Financial Results with Record Cash Generation - TipRanks
Earnings Flash (ALC) ALCON Reports Q4 Adjusted EPS $0.72, vs. FactSet Est of $0.71 - Marketscreener.com
Earnings Flash (ALC) ALCON Posts Q4 Revenue $2.48B, vs. FactSet Est of $2.47B -February 25, 2025 at 04:38 pm EST - Marketscreener.com
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation - Business Wire
Vitreous Tamponades Market Is Booming Worldwide 2025-2032 | - openPR
Contact Lens Market Projected To Witness Substantial Growth, 2025-2032:Alcon Vision LLC, EssilorLuxottica, - EIN News
Stifel maintains Buy on Alcon stock with $100 target By Investing.com - Investing.com Australia
Systane Eye Drop Recall Lawsuit Filed Against Alcon Over Fungal Contamination Risk - ClassAction.org
Alcon Debut New Eye Drop Product in US -February 24, 2025 at 09:00 am EST - Marketscreener.com
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.58%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):